SIA
ZOM

Soltis Investment Advisors’s Zomedica Corp. ZOM Stock Holding History

Soltis Investment Advisors’s Portfolio ZOM Stock Details ZOM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-12,000
Closed -$2.4K – 318
2023
Q4 		$2.4K Buy
+12,000
New +$2.11K ﹤0.01% 284

Other funds holding ZOM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBHC
Brown Brothers Harriman & Co New York $18.6B AUM 15.81% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
AI
Atom Investors Austin, Texas $1.4B AUM 23.77% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Soltis Investment Advisors's ZOM Position: Q1 2024 in Review

Soltis Investment Advisors sold out of Zomedica Corp. (ZOM) in Q1 2024, closing a stake of 12,000 shares — an estimated $2.4K sold.

Soltis Investment Advisors first reported a position in ZOM in Q4 2023 and held it in 1 quarter. The position peaked at $2.4K in Q4 2023. 99 funds tracked by Wall St. Rank hold ZOM as of Q1 2024.

  • Soltis Investment Advisors reported no remaining Zomedica Corp. position as of Q1 2024 after selling out during the quarter.
  • Soltis Investment Advisors sold 12,000 Zomedica Corp. shares in Q1 2024, an estimated $2.4K.
  • Soltis Investment Advisors first reported a position in Zomedica Corp. in Q4 2023 and held it in 1 quarter.
  • Soltis Investment Advisors's Zomedica Corp. position peaked at $2.4K in Q4 2023.
  • 99 funds tracked by Wall St. Rank held Zomedica Corp. as of Q1 2024.

Based on Soltis Investment Advisors's 13F filing for Q1 2024, filed 29 Apr 2024.